Eltoprazine is primarily studied for its potential therapeutic applications in addressing behavioral and neurological disorders. It has shown promise in managing aggression and impulsivity, making it a candidate for treating conditions like ADHD and intermittent explosive disorder. Additionally, its serotonin receptor modulation properties are being explored for potential use in alleviating symptoms of Parkinson’s disease, particularly in reducing levodopa-induced dyskinesia. Research also suggests its potential in addressing anxiety and depression due to its influence on serotonin pathways. Its unique pharmacological profile continues to be investigated for broader psychiatric and neurological applications. However, its use is still in the research and development stage and has not been widely approved for human use.